Current and future use of colchicine in patients with COVID-19
https://doi.org/10.37489/2588-0519-2020-S4-71-74
Abstract
There exist some theoretical premises for the use of colchicine in patients with COVID-19, and clinical trials are underway. There is currently no published evidence confirming effectiveness and safety of colchicine in COVID-19 and allowing to recommend it for general practice. If prescribing colchicine, the one should perform clinical and hematological monitoring and avoid drug interactions.
About the Authors
Yu. Yu. Kiselev
Oslo Metropolitan University
Norway
Norway
Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet
Oslo
A. V. Matveev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320
Moscow
D. A. Sychev
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556
Moscow
References
1. https://grls.rosminzdrav.ru/
2. https://www.medicines.org.uk/emc/product/6415/smpc
3. Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013 May;14(5):454-60. DOI: 10.1038/ni.2550
4. Hemkens LG, Ewald H, Gloy VL et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016 Jan 27;2016(1):CD011047. DOI: 10.1002/14651858.CD011047.pub2
5. Tardif JC, Kouz S, Waters DD et al. Efficacy and Safety of LowDose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. DOI: 10.1056/NEJMoa1912388
6. Leung YY, Hui LLY, Kraus VB. Colchicine-update on mechanism of action and therapeutic uses. Semin Arthritis Rheum. 2015 Dec;45(3):341-50. DOI: 10.1016/j.semarthrit.2015.06.013
7. Milewska A, Nowak P, Owczarek K et al. Entry of human coronavirus NL63 into the cell. J Virol. 2018;92:e01933-17. DOI: 10.1128/JVI.01933-17
8. Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64(12):1420-3
9. Piantoni S, Patroni A, Toniati P et al. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease [Access publication 2020 May 30]. Rheumatology (Oxford). 2020;59:1769-1770. DOI: 10.1093/rheumatology/keaa217
10. Nasiripour S, Zamani F, Farasatinasab M. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19? [Access publication 2020 May 23]. J Clin Pharmacol. 2020 Jul;60(7):828-829. DOI: 10.1002/jcph.1645
11. https://covid19evidence.net.au/
12. https://www.covid19treatmentguidelines.nih.gov/
13. https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf
14. https://www.canada.ca/en/public-health/services/diseases/2019-novelcoronavirus-infection/clinical-management-covid-19.html
15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/pdf/idr-121-8543.pdf
16. http://mc.msu.ru/protokol-COVID-MNOC.pdf?fbclid=IwAR0pcfEk_LpYL8O6YKNGEbe3b_FuEpYTbiap8JTH6ZhnVjYLzTFtHBKpYNY
17. Della-Torre E, Della-Torre F, Kusanovic Pcp M et al. Treating COVID-19 with colchicine in community healthcare setting [Access publication 2020 May 31]. Clin Immunol. 2020 Aug;217:108490. DOI: 10.1016/j.clim.2020.108490
18. Cumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? [Access publication 2020 May 11]. Clin Rheumatol. 2020 Jul;39(7):2101-2102. DOI:10.1007/s10067-02005144-x
19. Gendelman O, Amital H, Bragazzi NL et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020 Jul;19(7):102566. DOI: 10.1016/j.autrev.2020.102566
20. https://www.fda.gov/drugs/postmarket-drug-safety-information-patientsand-providers/colchicine-marketed-colcrys-information
21. https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=
Review
For citations:
Kiselev Yu.Yu., Matveev A.V., Sychev D.A. Current and future use of colchicine in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(4S):71-74. (In Russ.) https://doi.org/10.37489/2588-0519-2020-S4-71-74
Views:
6016
Email this article 